Hanall Biopharma Co., Ltd. (KRX:009420)

Hanall Biopharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 25, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2,352,488	1,959,952	2,245,705	902,290	1,077,892	1,919,220
Market Cap Growth	3.55%	-12.72%	148.89%	-16.29%	-43.84%	3.31%
Enterprise Value	2,341,906	1,934,197	2,185,410	836,710	991,822	1,831,333
Last Close Price	46350.00	38650.00	44300.00	17800.00	21050.00	37500.00
PE Ratio	1018.25	-	640.06	3588.03	121.16	97.10
Forward PE	325.38	117.15	261.09	112.30	65.12	88.99
PS Ratio	15.27	14.11	16.65	8.20	10.61	21.66
PB Ratio	14.92	11.64	12.06	5.36	6.59	10.59
P/TBV Ratio	24.48	11.96	12.18	5.43	6.68	10.74
P/FCF Ratio	188.64	253.93	82.47	40.22	-	-
P/OCF Ratio	169.64	209.40	75.76	35.71	1283.40	2065.25
PEG Ratio	-	19.09	19.09	19.09	19.09	30.69
EV/Sales Ratio	15.20	13.92	16.20	7.61	9.76	20.67
EV/EBITDA Ratio	-	577.20	437.93	183.55	77.34	207.41
EV/EBIT Ratio	-	8392.22	1253.51	555.66	98.21	308.56
EV/FCF Ratio	187.79	250.60	80.26	37.30	-	-
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.01	0.00
Debt / EBITDA Ratio	0.18	0.43	0.26	0.29	0.10	0.06
Debt / FCF Ratio	0.11	0.19	0.05	0.06	-	-
Asset Turnover	0.74	0.61	0.60	0.53	0.49	0.43
Inventory Turnover	1.95	1.88	2.08	2.11	2.05	2.26
Quick Ratio	0.82	1.29	2.10	2.97	4.35	4.61
Current Ratio	2.01	2.46	3.02	3.92	5.37	5.61
Return on Equity (ROE)	1.40%	-1.02%	1.98%	0.15%	5.16%	12.29%
Return on Assets (ROA)	1.16%	0.06%	0.48%	0.46%	3.02%	1.80%
Return on Capital (ROIC)	1.45%	0.08%	0.61%	0.56%	3.64%	2.30%
Return on Capital Employed (ROCE)	2.30%	0.10%	0.90%	0.80%	5.70%	3.00%
Earnings Yield	0.10%	-0.09%	0.16%	0.03%	0.83%	1.03%
FCF Yield	0.53%	0.39%	1.21%	2.49%	-0.35%	-0.08%
Buyback Yield / Dilution	1.06%	-0.04%	0.24%	0.76%	-0.05%	-0.00%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.